Status:
UNKNOWN
Cancer Treatment Related Cardiovascular Toxicity: Comprehensive Myocardial and Vascular Phenotyping
Lead Sponsor:
University College, London
Conditions:
Cardiovascular Diseases
Cardiotoxicity
Eligibility:
All Genders
18+ years
Brief Summary
Observational prospective cohort study designed to assess the mechanisms of fluoropyrimidine induced cardiovascular toxicity.
Detailed Description
Fluoropyrimidine (5-FU and Capecitabine) based chemotherapy regimens form the cornerstone of treatments for gastrointestinal (GI) cancers. Fluoropyrimidines however, are associated with the developmen...
Eligibility Criteria
Inclusion
- Age \>18 years
- Gastrointestinal malignancy
- Receiving fluoropyrimidine chemotherapy
Exclusion
- Participants unable or unwilling to provide consent
- Participants that have a conventional contraindication for magnetic resonance imaging (MRI) including permanent implantable cardiac devices, ferromagnetic implants, pregnancy, large body size not fitting into the scanner bore and severe claustrophobia will be excluded
- Participants that have a conventional contraindication for adenosine stress perfusion including a history of trifascicular block or of second-degree heart block or higher on ECG, or uncontrolled asthma.
- Participants with significant renal impairment (eGFR\<30ml/min)
- History of allergy to adenosine, gadolinium or iodinated contrast
- Patients with terminal illness (life expectancy \<6 months) will be excluded.
Key Trial Info
Start Date :
May 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06048458
Start Date
May 18 2022
End Date
February 1 2024
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Bartholomews Hospital
London, United Kingdom, EC1A 7BE